Teladoc Health stock drops after guidance cut as securities probe begins
Teladoc Health shares fell over 28% after it reported $606.9M in Q2 2026 revenue and lowered its full-year 2026 revenue guidance. Levi & Korsinsky said it is investigating TDOC securities and urges shareholders with documented losses to seek evaluation, noting eligibility depends on purchase date and does not require court appearances or depositions.